bioRxivPhysiologyPreprint
Enhancing mitochondrial pyruvate metabolism ameliorates myocardial ischemic reperfusion injury.
J. R. Visker, A. A. Cluntun, J. N. Velasco-Silva, D. R. Eberhardt, T. S. Shankar, R. Hamouche, J. Ling, H. Kwak, Y. Hillas, I. Aist, E. Tseliou, S. Navankasattusas, D. Chaudhuri, G. S. Ducker, S. G. Drakos, J. Rutter
Abstract
The established clinical therapy for the treatment of acute myocardial infarction is primary percutaneous coronary intervention (PPCI) to restore blood flow to the ischemic myocardium. PPCI is effective at reperfusing the ischemic myocardium, however the rapid re-introduction of oxygenated blood also can cause ischemia-reperfusion (I/R) injury. Reperfusion injury is the culprit for up to half of the final myocardial damage, but there are no clinical interventions to reduce I/R injury. We previously demonstrated that inhibiting the lactate exporter, monocarboxylate transporter 4 (MCT4), and re-directing pyruvate towards oxidation can blunt isoproterenol-induced hypertrophy. Based on this finding, we hypothesized that the same pathway might be important during I/R. Here, we establish that the pyruvate-lactate metabolic axis plays a critical role in determining myocardial salvage following injury. Post-I/R injury, the mitochondrial pyruvate carrier (MPC), required for pyruvate oxidation, is upregulated in the surviving myocardium following I/R injury. MPC loss in cardiomyocytes caused more cell death with less myocardial salvage, which was associated with an upregulation of MCT4 in the myocardium at risk of injury. We deployed a pharmacological strategy of MCT4 inhibition with a highly selective compound (VB124) at the time of reperfusion. This strategy normalized reactive oxygen species (ROS), mitochondrial membrane potential ({Delta}{psi}), and Ca2+, increased pyruvate entry to TCA cycle, and improved myocardial salvage and functional outcomes following I/R injury. Altogether, our data suggest that normalizing the pyruvate-lactate metabolic axis via MCT4 inhibition is a promising pharmacological strategy to mitigate I/R injury. GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=112 SRC="FIGDIR/small/577463v1_ufig1.gif" ALT="Figure 1"> View larger version (38K): org.highwire.dtl.DTLVardef@1a7a9b8org.highwire.dtl.DTLVardef@779e0aorg.highwire.dtl.DTLVardef@128d1f3org.highwire.dtl.DTLVardef@efc1bb_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: mouse
- assay: metabolomics
- research focus: cancer & tumor microenvironment
- research focus: cell signaling & trafficking
- research focus: metabolism & bioenergetics
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Inhibiting succinate release worsens cardiac reperfusion injury by enhancing mitochondrial reactive oxygen species generation
A. S. Milliken, S. M. Nadtochiy, P. S. Brookes·bioRxiv·Apr 27, 2022
- Improving Cardiac Resilience to Ischemia/Reperfusion: The Role of Butyrate in Mitochondrial and Metabolic Recovery
Bhuban Ruidas, William A. Michaud, … Seyed Alireza Rabi·AtherosclerosisPeer-reviewed·Feb 10, 2026
- Metallothionein-2A protect Cardiomyocytes from Ischemia/ Reperfusion through inhibiting p38
- Multi-omics map revealed PPARalpha activation protecting against myocardial ischemia-reperfusion injury by maintaining cardiac metabolic homeostasis
- Peroxisome proliferator-activated receptor gamma (PPARG)-mediated myocardial salvage in acute myocardial infarction managed with left ventricular unloading and coronary reperfusion
Joseph R. Visker, Eleni Tseliou, … Stavros Drakos·bioRxiv·Feb 11, 2025
- Lactylation landscape of mitochondrial proteins in myocardial infarction
Ashlesha A. Kadam, Shiridhar Kashyap, … Dhanendra Tomar·Redox BiologyPeer-reviewed·May 18, 2026